Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Shares Outstanding (Diluted Average) (2019 - 2025)

BioRestorative Therapies (BRTX) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $9.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Diluted Average) rose 12.25% year-over-year to $9.1 million, compared with a TTM value of $9.1 million through Sep 2025, up 12.25%, and an annual FY2024 reading of $7.8 million, up 84.05% over the prior year.
  • Shares Outstanding (Diluted Average) was $9.1 million for Q3 2025 at BioRestorative Therapies, up from $8.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $12.3 million in Q3 2023 and bottomed at $729930.0 in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $5.7 million, with a median of $5.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 99.94% in 2021, then surged 1088.25% in 2022.
  • Year by year, Shares Outstanding (Diluted Average) stood at $838689.0 in 2021, then skyrocketed by 331.37% to $3.6 million in 2022, then grew by 16.6% to $4.2 million in 2023, then soared by 84.05% to $7.8 million in 2024, then grew by 17.42% to $9.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BRTX at $9.1 million in Q3 2025, $8.6 million in Q2 2025, and $8.4 million in Q1 2025.